Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BEAM, BOL, KERA, LASE, LCAV, LVCI, LZRC, VISX, SNRS, STAA -- Ignore unavailable to you. Want to Upgrade?

To: Stanley L. Freedman who wrote (49)	4/15/1999 11:09:00 AM
From: Joe	Read Replies (1) \| Respond to of 253

Stanley, I just sold my KERA on that and the hyperopia news. I posted my reason on the KERA YAHOO thread and will past it below. This is just my opinion. Do your own DD. Regards, jpublic89 . I just sold my KERA for a small profit today after the press release on hyperopic data. I went to ASCRS and have the following comments. I am not short and will not short since I think KERA may be successful in the future. I postulated on the KERA thread before I left for ASCRS that the stock market response to FDA approval may have been because KERA might have built their advertising strategy around reversibility which FDA specifically disallowed in advertising. In talking with people in their booth, indeed they did consider reversibility a key to the success of the product. They said that over 90% of the post-op patients listed reversibility as the #1 reason for selecting the ring over a laser procedure. I decided to sell because management demonstrated bad judgment in that, 1) it was not prepared for approval, and 2) it was not prepared for FDA's restriction. The announcement of FDA approval at ASCRS was a sign hung in the booth that was obviously made up the day the show opened. Booth staff told me that the way they found out they got approval was on the internet. I heard that they may need to collect some clinical data, or more clinical data, on the reversibility. To me, this is an unbelievable string of failures of management. On the positive side I heard Canadian sales had been good and that you can look forward to a good Q1 report for KERA. jpublic89

To: Stanley L. Freedman who wrote (49)	4/16/1999 9:51:00 PM
From: neelu	Read Replies (1) \| Respond to of 253

Sorry Stan.,but I don't know enough about this to comment-good luck